EFEXOR XR 150MG 14CAP

Indications

Off-Label Uses

Commonly used off-label for neuropathic pain (including diabetic neuropathy), migraine prophylaxis, menopausal hot flashes/vasomotor symptoms, and PTSD (evidence varies).

Dosage & Administration

Initial Dose

75mg once daily (37.5mg once daily for panic disorder)

Maintenance Dose

75mg to 225mg once daily.

Maximum Dose

225mg per day for most indications.

Children's Dosage

Not approved for children or adolescents under 18 years

Dose Adjustment Notes

Titrate gradually based on response/tolerability (commonly in 75 mg increments at intervals of at least several days); reduce total daily dose in renal impairment and in hepatic impairment (often ~50% reduction), and taper gradually when discontinuing to minimize withdrawal symptoms.

Safety & Warnings

Contraindications

Hypersensitivity to venlafaxine/desvenlafaxine or any excipients; concomitant use with MAOIs or within 14 days of stopping an MAOI (and allow at least 7 days after stopping venlafaxine before starting an MAOI).

Warnings & Precautions

Monitor for clinical worsening/suicidality (especially in patients <25) during initiation and dose changes; risk of serotonin syndrome with serotonergic agents/MAOI-type drugs; monitor blood pressure (dose-related increases); use caution in seizure disorders and bipolar disorder (mania/hypomania); risk of hyponatremia/SIADH (higher in elderly/diuretics); increased bleeding risk with antiplatelets/NSAIDs/anticoagulants; taper gradually to avoid discontinuation syndrome; mydriasis/angle-closure glaucoma risk-use caution in patients with raised intraocular pressure/narrow angles; consider cardiac risk/ECG monitoring in overdose or high-risk patients.

Age Restriction

Not approved under 18 years.

Drug Interactions

Interaction Severity

MAJOR/contraindicated: MAOIs (including linezolid and IV methylene blue) due to serotonin syndrome risk. MODERATE: other serotonergic agents (SSRIs/SNRIs, triptans, tramadol, lithium, St John’s wort) due to serotonin syndrome; anticoagulants/antiplatelets/NSAIDs due to bleeding risk; strong CYP2D6 inhibitors may alter venlafaxine/ODV exposure (clinical significance varies).

Food Interaction

Take with food.

Special Populations

Pregnancy

Caution

Children

Not approved for children or adolescents under 18 years

Elderly

No specific dose adjustment required based on age alone; however, start at lower doses and titrate cautiously. Monitor blood pressure and serum sodium closely due to increased risk of hyponatremia and falls

Liver Impairment

Mild-to-moderate hepatic impairment (Child-Pugh A-B): reduce total daily dose by ~50%. Severe hepatic impairment/cirrhosis (Child-Pugh C): reduce by ≥50% (often more) and titrate cautiously.

Storage & Patient Advice

Patient Counseling

Take once daily with food; swallow XR capsule whole (do not crush/chew/open). Do not stop abruptly-taper with prescriber to avoid withdrawal. Expect benefit to build over several weeks. Avoid alcohol and use caution with driving until effects are known. Monitor/report elevated blood pressure, worsening mood/suicidal thoughts, and symptoms of serotonin syndrome (agitation, confusion, sweating, tremor, fast heartbeat). Tell clinicians about all medicines/herbals (e.g., St John’s wort, triptans, tramadol, NSAIDs/anticoagulants).

Monitoring Requirements

Monitor blood pressure (baseline and periodically) and heart rate; monitor for clinical worsening/suicidality especially early and after dose changes; monitor for serotonin syndrome when combined with serotonergic drugs; consider serum sodium in at-risk patients (e.g., elderly/diuretics) and weight.

Pharmacology

Duration of Effect

Antidepressant/anxiolytic clinical effect is sustained with continued daily dosing; each extended-release dose provides ~24-hour coverage.

Half-Life

Venlafaxine (parent drug): ~5 hours. O-desmethylvenlafaxine (active metabolite): ~11 hours.

Bioavailability

Approximately 45% (venlafaxine); XR provides slower absorption with similar overall bioavailability compared with immediate-release.

Metabolism

Extensive hepatic metabolism primarily via CYP2D6 to active O-desmethylvenlafaxine (ODV), with minor contribution from CYP3A4 and other pathways.

Protein Binding

Low protein binding: venlafaxine ~27% and ODV ~30%.

Product Information

OTC Alternatives

No OTC alternative

Psych Class

Antidepressant-SNRI

Controlled Substance

No

Legal Disclaimer - Al Mujtama Pharmacy

The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Al Mujtama Pharmacy assumes no legal or medical liability for:

• Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
• Any discrepancy between the information provided and the product's package insert or SFDA guidelines
• Any misuse of medication resulting from personal interpretation of the content displayed

Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.

By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.

Your health is a trust - always consult your doctor first.